blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4017486

EP4017486 - COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  27.05.2022
Database last updated on 20.05.2024
FormerThe international publication has been made
Status updated on  26.02.2021
Most recent event   Tooltip19.03.2024The date on which the examining division becomes responsible, has been established 
19.03.2024Amendment by applicant 
Applicant(s)For all designated states
Buzzelet Development And Technologies Ltd
P.O.B. 156
35, Ha-Ilan
Or-Akiva, 3065101 / IL
[2022/26]
Inventor(s)01 / EYAL, Aharon
16 Levy Street
936291 Jerusalem / IL
02 / RAZ, Noa
31 Gizo
9974500 Gizo / IL
 [2022/26]
Representative(s)Harrison IP Limited
3 Ebor House
Millfield Lane
Nether Poppleton
York YO26 6QY / GB
[N/P]
Former [2022/26]Harrison IP Limited
3 Ebor House
Millfield Lane
Nether Poppleton, York YO26 6QY / GB
Application number, filing date20854973.319.08.2020
[2022/26]
WO2020IB57805
Priority number, dateUS201962888560P19.08.2019         Original published format: US 201962888560 P
US201962888562P19.08.2019         Original published format: US 201962888562 P
[2022/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021033149
Date:25.02.2021
Language:EN
[2021/08]
Type: A1 Application with search report 
No.:EP4017486
Date:29.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 25.02.2021 takes the place of the publication of the European patent application.
[2022/26]
Search report(s)International search report - published on:IL25.02.2021
(Supplementary) European search report - dispatched on:EP23.08.2023
ClassificationIPC:A61K31/352, A61K31/01, A61K31/05, A61K31/164, A61P1/08, A61P3/10, A61P17/00, A61P25/06, A61P25/00, A61P29/00
[2022/26]
CPC:
A61P1/08 (EP); A61K31/16 (US); A61K31/01 (EP,US);
A61K31/05 (EP,US); A61K31/164 (EP); A61K31/192 (EP);
A61K31/352 (EP,US); A61K45/06 (EP); A61P17/00 (EP);
A61P25/00 (EP); A61P25/06 (EP); A61P29/00 (EP);
A61P3/10 (EP) (-)
C-Set:
A61K31/01, A61K2300/00 (EP);
A61K31/05, A61K2300/00 (EP);
A61K31/164, A61K2300/00 (EP);
A61K31/192, A61K2300/00 (EP);
A61K31/352, A61K2300/00 (EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/26]
TitleGerman:ZUSAMMENSETZUNGEN ZUR BEHANDLUNG EINES DURCH ANANDAMID-MANGEL GEKENNZEICHNETEN ZUSTANDES UND DEREN VERWENDUNGEN[2022/26]
English:COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF[2022/26]
French:COMPOSITIONS POUR LE TRAITEMENT D'UN ÉTAT CARACTÉRISÉ PAR UNE DÉFICIENCE EN ANANDAMIDE ET LEURS UTILISATIONS[2022/26]
Entry into regional phase17.03.2022National basic fee paid 
17.03.2022Search fee paid 
17.03.2022Designation fee(s) paid 
17.03.2022Examination fee paid 
Examination procedure17.03.2022Examination requested  [2022/26]
19.03.2024Amendment by applicant (claims and/or description)
19.03.2024Date on which the examining division has become responsible
Fees paidRenewal fee
17.03.2022Renewal fee patent year 03
23.07.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]US2018169035  (EYAL AHARON M [IL]) [X] 1-5,8-11,13,14 * page 1, paragraph 4 * * pages 1-2, paragraphs 12-15 * * pages 11-12; table 1 * [I] 6,7,12,15;
 [X]WO2019089583  (ENDOCANNA HEALTH INC [US]) [X] 1-5,8-14 * page 2, line 25 - page 4, line 18 * * page 38; table 1 *;
 [E]WO2020234650  (TIMELESS HERBAL CARE CANADA LTD [CA]) [E] 1-5,8-14 * page 1, paragraph 2 * * page 3, paragraphs 8-9 ** page 32; tables 1, 2 *
International search[XY]US2018078523  (SHMULEWITZ ASCHER [IL], et al) [X] 1-14,16-18,20,21,23, 24,27-38 * abstract, para. [0003], [0011], [0016], [0020], [0022], [0036], [0051], [0054]-[0057], [0065]-[0066], [0109]-[0117], [0119], [0121], [0124] abstract, para. [0003], [0011], [0016], [0020], [0022], [0036], [0051], [0054]-[0057], [0065]-[0066], [0109]-[0117], [0119], [0121], [0124] * [Y] 1-39;
 [XY]WO2019034936  (BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD [IL]) [X] 1-12,14-24,26-39 * abstract, para. [0006], [0008], [0012], [0023], [00134], [00586], [00581] abstract, para. [0006], [0008], [0012], [0023], [00134], [00586], [00581] * [Y] 1-39;
 [XY]  - NAHLER G. et al., "Cannabidiol and Contributions of Major Hemp Phytocompounds to the ''Entourage Effect''; Possible Mechanisms", J. Altern. Complementary Integr. Med, (20190516), vol. 5, doi:10.24966/ACIM-7562/100066, pages 1 - 16, XP055802342 [X] 1-12,14,16-23,27-37 * the whole document the whole document * [Y] 1-39

DOI:   http://dx.doi.org/10.24966/ACIM-7562/100070
 [A]  - ETHAN B. RUSSO, "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment- Resistant Syndromes", Cannabis Cannabinoid Res., (20170701), vol. 1, no. 1, doi:10.1089/ can.2016.0009, pages 154 - 165, XP055802344 [A] 1-39 * abstract, p. 155 left column, 156, 159 right column, 160 right column, 161-162, 163 left column *

DOI:   http://dx.doi.org/10.1089/can.2016.0009
 [A]  - ARAN A . et al., "Lower circulating endocannabinoid levels in children with autism spectrum disorder", Mol. Autism, (20190130), vol. 10, no. 1, doi:10.1186/sl3229-019-0256-6, pages 1 - 11, XP055802345 [A] 1-39 * abstract, p. 2, 4, 7-9 *

DOI:   http://dx.doi.org/10.1186/s13229-019-0256-6
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.